MRRPhysical AI
intelligence

← Company intelligence

Robot maker · early

Vexev

Corporate marketmedicalCurated record

VxWave is a robotic tomographic ultrasound platform combining robotics, AI and ultrasound to automate vascular image acquisition, initially for dialysis vascular access monitoring. In clinical trials non-specialist staff achieved a 94 percent autonomous acquisition success rate. Pursuing FDA 510(k) clearance; multi-site study with U.S. Renal Care clinics, so no commercial deployment yet.

HeadquartersSydney, AU

Founded2018

Corporate funding$19M

TeamNot listed

Deployments1

Open roles0

01

Company overview

Identity and operating footprint

Company typeRobot maker

Market segmentCorporate

StageSeed extension

FoundersJohn Carroll (Co-founder and CEO), Eamonn Colley (Co-founder)

Regions servedAU, US

Countries deployedNot listed

Service footprintNot listed

Last reviewed2026-10-13

LinkedInView profile

XNot listed

MX

Robot models

Specifications remain vendor-claimed

Machinemedical

VxWave

94% success rate for autonomous imaging acquisition by non-specialist clinical staff in clinical trials
Autonomous acquisition success rate
Claim source

DP

Deployment log

Announced and cited only

Announced	Customer	Site	Country	Count	Evidence
2025-07-29	U.S. Renal Care	dialysis clinics (CANSCAN clinical trial)	US	Not disclosed	Announcement

CA

Funding history

Publicly announced rounds

2026-08-06$6M

Seed extension

TreeArc Investment Group, TEN13, Bioshore Ventures, Blackbird Ventures

2022-11-14$6M

Seed-1

Neotribe Ventures, Blackbird Ventures

Investors on recordBlackbird VenturesNeotribe VenturesStartmateHorizonTreeArc Investment GroupTEN13

TL

Company timeline

Milestones and announcements

2026-08-06Raises $6M to pursue FDA 510(k) clearance and U.S. commercialization of VxWavePR Newswire

2026-08-06Vexev raises $6M for robotic ultrasound ↗MassDevice

SC

Source ledger

3 unique public sources

Vexev raises $6M to accelerate U.S. commercialization of autonomous vascular imaging platformPR Newswire · retrieved 2026-10-13

HSF advises Vexev on its USD$6 million Seed-1 capital raising led by Neotribe Ventures and Blackbird VenturesHerbert Smith Freehills via Mirage News · retrieved 2026-10-13

Vexev and U.S. Renal Care complete enrollment in CANSCAN trialAAP / Cision · retrieved 2026-10-13